publication date: Feb. 17, 2017

Funding Opportunities PCRP announces research awards application guidelines

The Department of Defense Prostate Cancer Research Program is pre-announcing the application process for its funding awards even though due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

Applicants can review general application instructions for the following award mechanisms, which are anticipated to be posted on Grants.gov in April 2017. Pre-application and application deadlines will be available when the program announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the PCRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency’s Research and Development Directorate manages the Defense Health Program’s Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated program announcements/funding opportunities is the Congressionally Directed Medical Research Programs.

The PCRP’s FY17 mission is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. As … Continue reading PCRP announces research awards application guidelines

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.